Molecular Glue Degraders of the HuR RNA Binding Protein to Treat BRAF-Mutant Colorectal Cancer
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo Sapiens
SUBMITTER: 
Yong Cang
PROVIDER: PXD066736 | iProX | Tue Jul 29 00:00:00 BST 2025
REPOSITORIES: iProX
Similar Datasets
Project description:BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, though approved therapies, results in short survival benefits and frequent treatment resistance and relapse1-3. Here, through rational chemical library design coupled with parallel proteomic screening, we identified dHuR as a molecular glue degrader of human antigen R (HuR), an RNA-binding protein that drives tumor growth, invasion, and therapy resistance. dHuR binds the CRBN ubiquitin ligase to create a unique benzofuran-tethered composite surface to recruit HuR as a neosubstrate by engaging its β-hairpin G-loop degron, as revealed by Cryo-EM structure of the ternary complex. dHuR abrogated BRAF expression by inducing its exon 18 skipping, and demonstrated superior suppr
2026-04-19 | PXD077365 |
Project description:BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, though approved therapies, results in short survival benefits and frequent treatment resistance and relapse1-3. Here, through rational chemical library design coupled with parallel proteomic screening, we identified dHuR as a molecular glue degrader of human antigen R (HuR), an RNA-binding protein that drives tumor growth, invasion, and therapy resistance. dHuR binds the CRBN ubiquitin ligase to create a unique benzofuran-tethered composite surface to recruit HuR as a neosubstrate by engaging its β-hairpin G-loop degron, as revealed by Cryo-EM structure of the ternary complex. dHuR abrogated BRAF expression by inducing its exon 18 skipping, and demonstrated superior suppression of BRAF mutant CRC tumors including those gaining resistance to BRAF inhibitors. Finally, we performed kinome library CRISPR screening and revealed that inactivation of EGFR or MEK enhanced dHuR cytotoxicity, thus establishing a combinatorial strategy to treat refractory BRAF-mutant CRC patients.
2025-12-21 | PXD072281 |
Project description:Molecular glue degraders represent a rapidly expanding class of small molecules that reprogram E3 ubiquitin ligases to ubiquitinate and degrade disease-relevant proteins. Despite their therapeutic potential, the rational design of molecular glues remains challenging, underscoring the need for unbiased discovery strategies to identify new chemical targets. To address this challenge, we developed ProxiCapture, an affinity-based proteomics workflow that models the systemic behavior of molecular glues (MGs) by combining purified CRBN-ΔHBD protein with native cell or tissue lysates. ProxiCapture enables proteome-wide identification of degrader-dependent CRBN-protein interaction across diverse biological contexts.
2026-02-03 | PXD070945 | Pride
Project description:Molecular glue degraders represent a rapidly expanding class of small molecules that reprogram E3 ubiquitin ligases to ubiquitinate and degrade disease-relevant proteins. Despite their therapeutic potential, the rational design of molecular glues remains challenging, underscoring the need for unbiased discovery strategies to identify new chemical targets. To address this challenge, we developed ProxiCapture, an affinity-based proteomics workflow that models the systemic behavior of molecular glues (MGs) by combining purified CRBN-ΔHBD protein with native cell or tissue lysates. ProxiCapture enables proteome-wide identification of degrader-dependent CRBN-protein interaction across diverse biological contexts.
2026-02-03 | PXD070656 | Pride
Project description:Molecular glue degraders represent a rapidly expanding class of small molecules that reprogram E3 ubiquitin ligases to ubiquitinate and degrade disease-relevant proteins. Despite their therapeutic potential, the rational design of molecular glues remains challenging, underscoring the need for unbiased discovery strategies to identify new chemical targets. To address this challenge, we developed ProxiCapture, an affinity-based proteomics workflow that models the systemic behavior of molecular glues (MGs) by combining purified CRBN-ΔHBD protein with native cell or tissue lysates. ProxiCapture enables proteome-wide identification of degrader-dependent CRBN-protein interaction across diverse biological contexts.
2026-02-05 | PXD073192 | Pride
Project description:Molecular glue degraders represent a rapidly expanding class of small molecules that reprogram E3 ubiquitin ligases to ubiquitinate and degrade disease-relevant proteins. Despite their therapeutic potential, the rational design of molecular glues remains challenging, underscoring the need for unbiased discovery strategies to identify new chemical targets. To address this challenge, we developed ProxiCapture, an affinity-based proteomics workflow that models the systemic behavior of molecular glues (MGs) by combining purified CRBN-ΔHBD protein with native cell or tissue lysates. ProxiCapture enables proteome-wide identification of degrader-dependent CRBN-protein interaction across diverse biological contexts.
2026-02-03 | PXD070567 | Pride
Project description:Molecular glue degraders represent a rapidly expanding class of small molecules that reprogram E3 ubiquitin ligases to ubiquitinate and degrade disease-relevant proteins. Despite their therapeutic potential, the rational design of molecular glues remains challenging, underscoring the need for unbiased discovery strategies to identify new chemical targets. To address this challenge, we developed ProxiCapture, an affinity-based proteomics workflow that models the systemic behavior of molecular glues (MGs) by combining purified CRBN-ΔHBD protein with native cell or tissue lysates. ProxiCapture enables proteome-wide identification of degrader-dependent CRBN-protein interaction across diverse biological contexts.
2026-02-03 | PXD070621 | Pride
Project description:Molecular glue degraders represent a rapidly expanding class of small molecules that reprogram E3 ubiquitin ligases to ubiquitinate and degrade disease-relevant proteins. Despite their therapeutic potential, the rational design of molecular glues remains challenging, underscoring the need for unbiased discovery strategies to identify new chemical targets. To address this challenge, we developed ProxiCapture, an affinity-based proteomics workflow that models the systemic behavior of molecular glues (MGs) by combining purified CRBN-ΔHBD protein with native cell or tissue lysates. ProxiCapture enables proteome-wide identification of degrader-dependent CRBN-protein interaction across diverse biological contexts.
2026-02-03 | PXD070637 | Pride
Project description:Overcoming drug resistance remains a major challenge in targeted therapy. Molecular glue degraders offer a promising solution, but their discovery has been largely serendipitous, limiting systematic development. In this study, we report a rational strategy to convert kinase inhibitors into molecular glue degraders that overcome Bcr-AblT315I-mediated resistance in chronic myeloid leukemia (CML). By engineering the solvent-exposed region of GZD824, we generated a covalent degrader that recruits the previously unexploited E3 ligase UBR4 through covalent engagement of C4512. Structural optimization, which replaced the covalent warhead with a minimal ethyl group, yielded compound 4147. This compound achieved potent Bcr-AblT315I degradation (DC₅₀ = 16.18 nM, Dmax = 91.1%), displayed favorable pharmacokinetics (t1/2 = 4.36 h, F = 69.78%), and demonstrated strong in vivo efficacy (67.8% TGI at 20 mg/kg) with minimal toxicity (≤3% body weight loss), markedly outperforming olverembatinib (26.2% TGI). These findings establish 4147 as a clinically tractable molecular glue degrader to overcome T315I-mediated resistance in CML. More broadly, our design strategy can be applied to other marketed kinase inhibitors, such as imatinib (Gleevec) and ponatinib (Iclusig), through minimal structural modifications that preserve drug-like properties. Beyond its therapeutic implications, this work validates UBR4 as a previously unexploited E3 ligase for targeted protein degradation, thereby expanding the ligase repertoire and providing a general framework for the rational development of druggable molecular glue degraders.
2026-03-26 | PXD068712 |
Project description:Molecular glue degraders are an effective therapeutic modality, but their design principles are not well understood. Recently, several unexpectedly diverse compounds were reported to deplete cyclin K by linking CDK12-cyclin K to the DDB1-CUL4-RBX1 E3 ligase. To investigate how chemically dissimilar small molecules trigger cyclin K degradation, we evaluated 91 candidate degraders in structural, biophysical, and cellular studies and reveal all compounds acquire glue activity via simultaneous CDK12 binding and engagement of DDB1 interfacial residues, in particular Arg928. While we identify multiple published kinase inhibitors as cryptic degraders, we also show that these glues do not require pronounced inhibitory properties for activity and that the relative degree of CDK12 inhibition versus cyclin K degradation is tuneable. We further demonstrate cyclin K degraders have transcriptional signatures distinct from CDK12 inhibitors, thereby offering unique therapeutic opportunities. The systematic structure-activity relationship analysis presented herein provides a conceptual framework for rational molecular glue design.
2023-10-20 | PXD041836 | Pride